Identification of a potential biomarker for FABP4 inhibition: The power of lipidomics in preclinical drug testing

Journal of Biomolecular Screening

Volumn 16, Issue 5, 2011, Pages 467-475

  Suhre, Karsten ^a,b   Römisch Margl, Werner ^a   De Angelis, Martin Hrabé ^a,c   Adamski, Jerzy ^a,c   Luippold, Gerd ^d   Augustin, Robert ^d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

atherosclerosis; biomarkers; drug action; fatty acid binding protein; mass spectroscopy; metabolomics; type 2 diabetes

Indexed keywords

BMS 309403; FATTY ACID BINDING PROTEIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL DIFFERENTIATION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; LIPIDOMICS; MACROPHAGE; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CHEMOKINE CCL2; DRUG EVALUATION, PRECLINICAL; FATTY ACID-BINDING PROTEINS; HUMANS; LIPID METABOLISM; MACROPHAGES; MALE; MICE; PYRAZOLES;

MUS;

EID: 79959400390     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111402200     Document Type: Article

References (26)

1. Erion D. M., Shulman G. I.. Diacylglycerol-Mediated Insulin Resistance. Nat. Med. 2010 ; 16: 400-402
2. Pratico D., Dogne J. M.. Vascular Biology of Eicosanoids and Atherogenesis. Expert Rev. Cardiovasc. Ther. 2009 ; 7: 1079-1089
3. Cowart L. A.. Sphingolipids: Players in the Pathology of Metabolic Disease. Trends Endocrinol. Metab. 2009 ; 20: 34-42
4. Prieur X., Roszer T., Ricote M.. Lipotoxicity in Macrophages: Evidence from Diseases Associated with the Metabolic Syndrome. Biochim. Biophys. Acta. 2010 ; 1801: 327-337
5. Furuhashi M., Hotamisligil G. S.. Fatty Acid-Binding Proteins: Role in Metabolic Diseases and Potential as Drug Targets. Nat. Rev. Drug Discov. 2008 ; 7: 489-503 (Pubitemid 351767117)
6. Hotamisligil G. S., Johnson R. S., Distel R. J., Ellis R., Papaioannou V. E., Spiegelman B. M.. Uncoupling of Obesity from Insulin Resistance through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein. Science. 1996 ; 274: 1377-1379 (Pubitemid 26391462)
7. Uysal K. T., Scheja L., Wiesbrock S. M., Bonner-Weir S., Hotamisligil G. S.. Improved Glucose and Lipid Metabolism in Genetically Obese Mice Lacking aP2. Endocrinology. 2000 ; 141: 3388-3396 (Pubitemid 32269028)
8. Makowski L., Brittingham K. C., Reynolds J. M., Suttles J., Hotamisligil G. S.. The Fatty Acid-Binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity: Macrophage Expression of aP2 Impacts Peroxisome Proliferator-Activated Receptor gamma and IkappaB Kinase Activities. J. Biol. Chem. 2005 ; 280: 12888-12895
9. Makowski L., Boord J. B., Maeda K., Babaev V. R., Uysal K. T., Morgan M. A., Parker R. A., Suttles J., Fazio S., Hotamisligil G. S., et al. Lack of Macrophage Fatty-Acid-Binding Protein aP2 Protects Mice Deficient in Apolipoprotein E against Atherosclerosis. Nat. Med. 2001 ; 7: 699-705 (Pubitemid 32588026)
10. Lehmann F., Haile S., Axen E., Medina C., Uppenberg J., Svensson S., Lundback T., Rondahl L., Barf T.. Discovery of Inhibitors of Human Adipocyte Fatty Acid-Binding Protein, a Potential Type 2 Diabetes Target. Bioorg. Med. Chem. Lett. 2004 ; 14: 4445-4448 (Pubitemid 39043964)
11. Ringom R., Axen E., Uppenberg J., Lundback T., Rondahl L., Barf T.. Substituted Benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: A Novel Class of Selective Human A-FABP Inhibitors. Bioorg. Med. Chem. Lett. 2004 ; 14: 4449-4452 (Pubitemid 39043965)
12. Furuhashi M., Tuncman G., Gorgun C. Z., Makowski L., Atsumi G., Vaillancourt E., Kono K., Babaev V. R., Fazio S., Linton M. F., et al. Treatment of Diabetes and Atherosclerosis by Inhibiting Fatty-Acid-Binding Protein aP2. Nature. 2007 ; 447: 959-965 (Pubitemid 46975747)
13. Cao H., Gerhold K., Mayers J. R., Wiest M. M., Watkins S. M., Hotamisligil G. S.. Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism. Cell. 2008 ; 134: 933-944
14. Illig T., Gieger C., Zhai G., Romisch-Margl W., Wang-Sattler R., Prehn C., Altmaier E., Kastenmuller G., Kato B. S., Mewes H. W., et al. A Genome-Wide Perspective of Genetic Variation in Human Metabolism. Nat. Genet. 2010 ; 42: 137-141
15. Gieger C., Geistlinger L., Altmaier E., Hrabe de Angelis M., Kronenberg F., Meitinger T., Mewes H. W., Wichmann H. E., Weinberger K. M., Adamski J., et al. Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum. PLoS Genet. 2008 ; 4 :
16. Verollet R.. A Major Step towards Efficient Sample Preparation with Bead-Beating. Biotechniques. 2008 ; 44: 832-833 (Pubitemid 351839155)
17. Hettick J. M., Green B. J., Buskirk A. D., Kashon M. L., Slaven J. E., Janotka E., Blachere F. M., Schmechel D., Beezhold D. H.. Discrimination of Aspergillus Isolates at the Species and Strain Level by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Fingerprinting. Anal. Biochem. 2008 ; 380: 276-281
18. Wu H., Southam A. D., Hines A., Viant M. R.. High-Throughput Tissue Extraction Protocol for NMR- and MS-Based Metabolomics. Anal. Biochem. 2008 ; 372: 204-212 (Pubitemid 350116777)
19. Weinberger K. M.. Metabolomics in diagnosing metabolic diseases [in German]. Ther. Umsch. 2008 ; 65: 487-491
20. Altmaier E., Ramsay S. L., Graber A., Mewes H. W., Weinberger K. M., Suhre K.. Bioinformatics Analysis of Targeted Metabolomics: Uncovering Old and New Tales of Diabetic Mice under Medication. Endocrinology. 2008 ; 149: 3478-3489 (Pubitemid 351919596)
21. Wang-Sattler R., Yu Y., Mittelstrass K., Lattka E., Altmaier E., Gieger C., Ladwig K. H., Dahmen N., Weinberger K. M., Hao P., et al. Metabolic Profiling Reveals Distinct Variations Linked to Nicotine Consumption in Humans: First Results from the KORA Study. PLoS One. 2008 ; 3: e3863
22. Storey J. D.. The Positive False Discovery Rate: A Bayesian Interpretation and the q-Value. Ann. Stat. 2003 ; 31: 2013-2035 (Pubitemid 38293903)
23. Sulsky R., Magnin D. R., Huang Y., Simpkins L., Taunk P., Patel M., Zhu Y., Stouch T. R., Bassolino-Klimas D., Parker R., et al. Potent and Selective Biphenyl Azole Inhibitors of Adipocyte Fatty Acid Binding Protein (aFABP). Bioorg. Med. Chem. Lett. 2007 ; 17: 3511-3515 (Pubitemid 46824179)
24. Richieri G. V., Ogata R. T., Kleinfeld A. M.. Equilibrium Constants for the Binding of Fatty Acids with Fatty Acid-Binding Proteins from Adipocyte, Intestine, Heart, and Liver Measured with the Fluorescent Probe ADIFAB. J. Biol. Chem. 1994 ; 269: 23918-23930
25. Maeda K., Cao H., Kono K., Gorgun C. Z., Furuhashi M., Uysal K. T., Cao Q., Atsumi G., Malone H., Krishnan B., et al. Adipocyte/Macrophage Fatty Acid Binding Proteins Control Integrated Metabolic Responses in Obesity and Diabetes. Cell Metab. 2005 ; 1: 107-119 (Pubitemid 43960591)
26. Boord J. B., Maeda K., Makowski L., Babaev V. R., Fazio S., Linton M. F., Hotamisligil G. S.. Combined Adipocyte-Macrophage Fatty Acid-Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E-Deficient Mice. Circulation. 2004 ; 110: 1492-1498 (Pubitemid 39238029)